{"id":977416,"date":"2026-06-30T16:48:24","date_gmt":"2026-06-30T20:48:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-launch-of-public-offering-of-american-depositary-shares\/"},"modified":"2026-06-30T16:48:24","modified_gmt":"2026-06-30T20:48:24","slug":"abivax-announces-launch-of-public-offering-of-american-depositary-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-launch-of-public-offering-of-american-depositary-shares\/","title":{"rendered":"Abivax Announces Launch of Public Offering of American Depositary Shares"},"content":{"rendered":"
\n

\n Abivax Announces Launch of Public Offering of American Depositary Shares<\/strong>\n <\/p>\n

\n PARIS, France \u2013 June 30, 2026 \u2013 10:45 p.m. CEST <\/b>\u2013 Abivax SA<\/u><\/a> (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax<\/b>\u201d or the \u201cCompany<\/b>\u201d), a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the launch of an underwritten public offering of approximately $600 million (approximately \u20ac527 million)\u00a0of its American Depositary Shares (\u201cADSs<\/b>\u201d), each representing one ordinary share of Abivax, nominal value \u20ac0.01 per share (each, an \u201cOrdinary Share<\/b>\u201d), in the United States (the \u201cOffering<\/b>\u201d). The Offering is a public offering registered under the U.S. Securities Act of 1933, as amended. Abivax also expects to grant the underwriters of the Offering an option to purchase up to an additional fifteen percent (15%) of the total number of ADSs proposed to be sold in the Offering, on the same terms and conditions, exercisable through the day of initial settlement of the Offering.<\/p>\n

All ADSs to be sold in the Offering will be offered by the Company. The Company\u2019s ADSs are listed on The Nasdaq Global Market under the ticker symbol \u201cABVX.\u201d The Company\u2019s Ordinary Shares are listed on the regulated market of Euronext in Paris (\u201cEuronext<\/b>\u201d) under the symbol \u201cABVX.\u201d<\/p>\n

\n Key Characteristics of the Offering<\/b>\n <\/p>\n

The ADSs to be sold in the Offering will be issued by way of a capital increase without shareholders\u2019 preferential subscription rights through a public offering (other than public offerings as defined in Article L.411-2 1\u00b0 of the French Monetary and Financial Code (Code mon\u00e9taire et financier<\/i>)) in accordance with the 18th<\/sup>\u00a0and 27th<\/sup> resolutions of the Company\u2019s combined general meeting of shareholders held on May 11, 2026 (the \u201cGeneral Meeting<\/b>\u201d).<\/p>\n

The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering. The final amount of the Offering, the offering price of the ADSs in U.S. dollars, and the final number of ADSs to be sold in the Offering will be determined following a book-building process commencing immediately. The Company will announce the results of the Offering, including the number and subscription price of ADSs to be issued, as soon as practicable after pricing in a subsequent press release.<\/p>\n

The trading of the Company\u2019s Ordinary Shares on Euronext is expected to be suspended on July 1, 2026, until the opening of trading of the Company\u2019s ADSs on The Nasdaq Global Market at approximately 3:30 p.m. (Paris time) \/ 9:30 a.m. (New York time) on July 1, 2026, prior to which the Company is expected to publish the results of the Offering and the allocation of share capital to be effective following settlement and delivery of the ADSs sold in the Offering.<\/p>\n

The number of ADSs to be sold in the Offering will be determined by the Chief Executive Officer of the Company acting upon sub-delegation from the Company\u2019s Board of Directors in accordance with the delegation granted by the General Meeting, pursuant to its 18th<\/sup>\u00a0and 27th<\/sup>\u00a0resolutions.<\/p>\n

The offering price of the ADSs will be in U.S. dollars and will be set in compliance with the limitations set forth in the 18th<\/sup> resolution of the General Meeting (i.e., the offering price may not be less than the weighted average share price on Euronext over a period chosen by the Board of Directors of between three (3) and ninety (90) consecutive trading days preceding the determination of the issue price, possibly reduced, at the discretion of the Board of Directors, by a maximum discount of ten percent (10%)).<\/p>\n

The Offering will be subject to an underwriting agreement entered into with the underwriters of the Offering. The underwriting agreement will not constitute a performance guarantee (garantie de bonne fin<\/i>) within the meaning of Article L.225-145 of the French Commercial Code (Code de commerce<\/i>).<\/p>\n

Ordinary Shares underlying ADSs issued in the Offering will be subject to an application for admission to trading on Euronext on the same trading line as the existing Ordinary Shares of the Company currently listed on Euronext, under the same ISIN code FR0012333284.<\/p>\n

\n Anticipated Use of Proceeds<\/b>\n <\/p>\n

The Company intends to use the net proceeds from the Offering for:<\/p>\n